BioAge Labs to Present at Upcoming Investor Conferences

Webcast access and 30-day replays of BioAge Labs’ September 2026 investor-conference presentations will be available on its investor website.

Rhea-AI Summary

BioAge Labs (BIOA) will present at three investor conferences in New York in September 2026, featuring fireside chats and one-on-one meetings with senior management.

Events include the Citi Biopharma Back to School Conference (Sept 9–10), Cantor Global Healthcare Conference (Sept 9–11), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14–16), with webcast access and 30-day replays available via the company’s investor website.

News Market Reaction – BIOA

+1.84%

5 alerts

+1.84% Session close to close

$462.24M Market Cap

0.9x Rel. Volume

In the Sep 2 session, BIOA gained 1.84%, reflecting a mild positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• Citi Biopharma Back to School Conference (New York, September 9–10, 2026): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Wednesday, September 9 at 11:20–11:55 AM EDT. Kristen Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
• Cantor Global Healthcare Conference (New York, September 9–11, 2026): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Friday, September 11 at 10:20–10:50 AM EDT. Kristen Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
• Morgan Stanley 24th Annual Global Healthcare Conference (New York, September 14–16, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Wednesday, September 16 at 10:00–10:35 AM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the webcasts will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company’s lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including retinal diseases such as diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers in participants with obesity and elevated inflammatory markers such as hsCRP. Phase 2 proof-of-concept data are anticipated in the second half of 2026, and Phase 1b/2a diabetic macular edema proof-of-concept data are anticipated in mid-2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

Which investor conferences will BioAge Labs (BIOA) attend in September 2026?

BioAge Labs will participate in the Citi Biopharma Back to School Conference on September 9–10, the Cantor Global Healthcare Conference on September 9–11, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14–16, all in New York.

When is BioAge Labs (BIOA) presenting at the Citi Biopharma Back to School Conference?

At the Citi Biopharma Back to School Conference, CEO Kristen Fortney is scheduled for a fireside chat on Wednesday, September 9, 2026, from 11:20–11:55 AM EDT, and she and CFO Dov Goldstein will also hold one-on-one meetings.

What is the BioAge Labs (BIOA) schedule at the Cantor Global Healthcare Conference?

At the Cantor Global Healthcare Conference, CEO Kristen Fortney will participate in a fireside chat on Friday, September 11, 2026, from 10:20–10:50 AM EDT. She and CFO Dov Goldstein will also participate in one-on-one investor meetings.

When will BioAge Labs (BIOA) present at the Morgan Stanley 24th Annual Global Healthcare Conference?

At the Morgan Stanley 24th Annual Global Healthcare Conference, CFO Dov Goldstein and Chief Strategy Officer BJ Sullivan are scheduled for a fireside chat on Wednesday, September 16, 2026, from 10:00–10:35 AM EDT, and will also participate in one-on-one meetings.

How can investors access the BioAge Labs (BIOA) conference webcasts and replays?

Live webcasts for each fireside chat can be accessed via the provided registration links, and replays will be available in the investor section of BioAge Labs’ website at https://ir.bioagelabs.com/ for 30 days following the presentations.